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Abstract
Gastrointestinal diseases are associated with a lower quality of life (QoL), but relatively little is 
known about how this relationship scales with symptom severity, which can be highly variable. We 
studied how QoL scores changed over a range of gut health by measuring RAND SF-36 scores 
in clinical irritable bowel syndrome (IBS) patients and in patients with functional gastrointestinal 
disorders (FGIDs) from a general population cohort as compared to controls. Clinical IBS patients 
(patients with more severe gastrointestinal symptoms) had lower QoL scores than population-
based FGIDs patients (patients with milder gastrointestinal symptoms) and controls. The QoL 
scores in population-based FGIDs patients were also lower versus controls. In addition, we 
observed negative associations between total GI symptom score and the mental and physical 
component score of QoL. We thus conclude that higher gastrointestinal symptom scores can be 
linked to a greater reduction in QoL. 
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Introduction
Quality of life (QoL), also termed wellbeing, includes all emotional, social, and physical aspects 
of an individual’s life. It is well known that gastrointestinal diseases have a high impact on QoL.1 
In irritable bowel syndrome (IBS) patients, QoL is found to be lower than in healthy controls2,3 
and IBS QoL is also lower than that of patients with other common diseases like type 2 diabetes 
mellitus2 and cancer3. Gut health is characterized by multiple aspects which, taken together, lead 
to a range in presentation of gut health.4 One of these aspects is gastrointestinal (GI) symptom 
severity, and little is known about the association between this aspect of gut health and QoL. In 
this study we investigated how QoL is associated to different gradations of gut health as measured 
via Rome III criteria and GI symptoms.
Methods
QoL was assessed via the validated Dutch language version5 of the RAND 36-item Short Form 
Health Survey scoring version I (SF-36 Health Survey). We used our SF-36 Health Survey results 
to calculate eight summary scores and combined these into a composite mental component score 
(MCS) and a composite physical component score (PCS) (Figure 1). The summary scores range 
from zero to 100 points, where 100 represents the best QoL. The mental and physical component 
scores were transformed to have a mean of 50 and a standard deviation of 10 compared to the 
reference population, as described previously.6–9
FIGURE 1 | Contribution of the RAND SF-
36 summary scores to the mental and physical 
component score. All summary scores contribute 
to the MCS and PCS. Black lines connect the 
summary scores with the highest contribution to 
the component score. Dotted lines connect the 
summary scores that contribute less. Adapted 
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We studied how QoL was associated with functional gastrointestinal disorders and GI symptom 
severity in two cohorts: a case-control cohort of clinically diagnosed IBS patients (Maastricht 
IBS (MIBS), n=400)10 and a population cohort studied cross-sectionally (LifeLines Deep (LLD), 
n=1,158)11. In our LLD cohort, patients with functional gastrointestinal disorders (FGIDs) were 
diagnosed based on a self-administered Rome III questionnaire. In both cohorts the patient group 
included more women and more smokers compared to controls (Table 1). In the MIBS cohort, 
patients had a higher BMI compared to controls. Patients in the LLD cohort were on average a few 
years younger than controls (Table 1). Data on GI symptom severity was collected via a 7-day 
(LLD) or 14-day (MIBS) stool diary as described previously.11,12 In short, eight GI symptoms (e.g. 
bloating and diarrhea) were scored on a 5-point Likert scale over seven or fourteen consecutive 
days. The total GI symptom score was calculated by summing all scores for all eight symptoms 
over all days. In MIBS this score was divided by two to obtain a weekly GI symptom score. 
Participants with missing data (i.e. a total score below 56) were excluded from the analysis (n=81 
LLD, n=17 MIBS). Mean and SD summary and component scores for QoL were calculated per 
group, and groups were compared by ANCOVA adjusted for age and gender. We performed 
Spearman correlation analysis to study the association between GI symptoms and the mental 
and physical component score of QoL. All analyses were performed with the statistical package 
R version 3.2.1.
TABLE 1 | Gender, age, body mass index and smoking status of patients and controls in the clinical IBS patients cohort 
(MIBS) and the population cohort (LLD)
MIBS LLD
IBS Patients Controls FGIDs Patients Controls
n = 202 n = 198 n = 412 n = 746
Women n (%) 149 (73.8)* 120 (60.6) 300 (72.8)* 384 (51.5)
Age mean (SD) 45.2 (17.4) 45.7 (19.0) 43.1 (12.7)* 46.6 (14.0)
BMI mean (SD) 24.9 (4.4)* 24.0 (3.8) 25.3 (4.4) 25.2 (4.1)
Smoking n (%) 47 (23.3)* 13 (6.6) 98 (23.8)* 124 (16.6)
GI symptom score** mean (SD)# 106.8 (30.6)* 61.9 (7.9) 79.1 (21.3)* 62.9 (8.4)
IBS=irritable bowel syndrome, FGIDs=functional gastrointestinal disorders, BMI=body mass index, GI=gastrointestinal, * 
p<0.05 in patients versus controls within the cohort, ** GI symptom score is per week, # including only participants with 
complete GI symptom data (n=383 MIBS, n=1077 LLD)
Results and discussion
In both cohorts, we found significantly lower scores on all QoL domains for patients versus 
controls (Figure 2). The eight summary scores for QoL measured by RAND SF-36 questionnaire 
were comparable between controls from both cohorts (Figure 2, red and purple lines), whereas 
the clinically diagnosed IBS patients (Figure 2, blue line) scored significantly lower, and the 
population-based FGIDs patients (Figure 2, green line) scored between IBS patients and controls. 
Moreover, differences between the patient groups were significant on all eight summary domains 
(Figure 2). A previous study conducted in England in 100 students observed the same trend 
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in QoL scores in IBS patients as compared to those of IBS non-consulters (who had symptoms 
but had not sought medical attention) and controls. Both patient groups in the British study (IBS 
patients and IBS non-consulters) scored lower on all domains of QoL than controls, moreover IBS 
patients scored lower on “role physical”, “bodily pain”, “general health”, “vitality” and “social 

























Population-based FGIDs patients LLD
Controls LLD
FIGURE 2 | Quality of life scores (SF-36) in the Maastricht IBS cohort (MIBS) (blue and red) and LifeLines DEEP 
(LLD) (green and purple). PF=physical functioning, RP=role physical, BP=bodily pain, GH=general health, VT=vitality, 
SF=social functioning, RE=role emotional, MH=mental health. Lowercase letters indicate significant differences (p<0.05) 
between groups: a=IBS patients versus controls MIBS, b=population-based FGIDs patients versus controls LLD, c=IBS 
patients MIBS versus population-based FGIDs patients LLD, d=controls MIBS versus controls LLD. 
Controls from our LLD cohort scored lower on the domains ‘vitality’ and ‘general health’, but higher 
for ‘role emotional‘ compared to the MIBS controls. We postulate that the differences between 
the two control groups in our study originate from the fact that LLD controls are sampled from 
the general population rather than being chosen for their “healthy” status in the MIBS controls. 
Given that the prevalence of having at least one chronic disease ranges from 27.3% in individuals 
25-54 years old to 79.1% in individuals aged >75 years in the Netherlands14, the LLD controls 
might suffer from other non-GI diseases that also impact QoL. Another factor that might add to 
the differences in QoL summary scores between controls from both cohorts is socio economic 
status (SES) as QoL is known to be lower in persons with a lower SES15. Unfortunately SES data 
is not available in the studied cohorts. Our two cohorts also originate from different regions of 
the Netherlands (LLD from the North and MIBS from the South) and, although there is no region-
specific QoL data for the Netherlands, one could speculate that the regional differences might 
impact QoL as it has been shown to differ between countries16. 
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